Leveraging the Findings From First in-Human GSI-plus-BCMA Clinical Trial to Understand Mechanisms of Resistance & Optimize Efficacy

Time: 12:00 pm
day: Day One


  • Exploring why mechanisms of resistance to BCMA targeted therapies require further elucidation
  • Understanding the impact of BCMA antigen density on response, needing to be further characterized
  • Discussing why the approach to sequencing BCMA targeting agents may require careful consideration